88416-58-4Relevant articles and documents
Photo- and radiation-chemical production of radical cations of methylbenzenes and benzyl alcohols and their reactivity in aqueous solution
Russo-Caia, Claudia,Steenken, Steen
, p. 1478 - 1485 (2002)
Radical cations of methylated benzenes and benzyl alcohols were generated by photoionization and by reaction SO4·- in aqueous solution. The photoionization requires two 248 nm photons. The lifetimes with the oxidant SO4 and absorption spectra of the radical cations produced were determined by time-resolved conductance and optical detection, and the reaction products were measured by GC. As expected, the radical cation lifetimes increase strongly with increasing number of additional methyl groups, and so does the ratio of deprotonation from a methyl or hydroxymethyl group vs. addition (of water) to a ring position. In the case of toluene the radical cation appears to have a chemical lifetime τ of 10-100 ps ≤ τ ≤ 20 ns, i.e., longer than it takes for an ion pair to separate into the free (solvated) ions, and it reacts predominantly by addition of water to the ring rather than by deprotonation from the methyl group. A further observation is that, as compared to methoxylated analogues, the methylated benzyl alcohol radical cations are much more reactive, such that OH-induction of side-chain fragmentation, as often required with methoxylated benzyl alcohol-type radical cations, is not necessary.
HETEROAROMATIC COMPOUNDS AND USES THEREOF
-
, (2022/04/03)
Providing heteraromatic compounds and uses thereof. In particular, providing heteraromatic compounds of formula (I), pharmaceutical compositions comprising same, methods for preparing same and uses thereof, wherein the variables are as defined in the description.
INHIBITORS OF JANUS KINASES
-
Page/Page column 42, (2010/04/03)
The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3, TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.